newsfilter
← Latest News
GlobeNewswire·

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis

- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations- Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases NEW YORK and DURHAM, N.C., Nov. 01, 2021